It inhibits the NF‐kB signalling pathway, which is often associated with cancer progression, by reversibly targeting the 20S proteasome subunit and thus preventing the degradation of NF‐kB inhibitors [108, 109]. The gene discussed is NFKB1; the disease is cancer.